Polyphor Ltd, a privately held pharmaceutical company and partner in the NABATIVI project, and Roche announced today that they have entered into an exclusive worldwide license agreement to develop and commercialize Polyphor’s investigational macrocycle antibiotic, POL7080, for patients suffering from bacterial infections caused by Pseudomonas aeruginosa.
The NABATIVI Summer School concluded on July 3 following the successful participation of students and speakers from 12 countries. Held over 3 days at the San Raffaele Scientific Institute, Milan, Italy, the summer school attracted top academic and private sector researchers and clinicians to discuss
novel strategies for bacterial targets identification in the area of antibiotic discovery, with a focus on results from EU funded projects.
NABATIVI partner Polyphor recently announced the successful completion of a Phase I clinical trial demonstrating the clinical safety and tolerability of its Pseudomonas specific antibiotic POL7080.
Click here for the Press release